Medicine and condoms give Reckitt a lift
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Demand for bathroom-cabinet and bedside-drawer staples from Strepsils to Nurofen and Durex is soaring, Reckitt Benckiser reported yesterday.
That helped send the consumer goods giant's revenues up 7 per cent to £2.5bn for the first three months of the year.
Rakesh Kapoor, Reckitt's chief executive, who pocketed £6.3m in pay and share bonuses last year, said an extra-vicious flu season had helped revenues grow. "Mucinex and Strepsils have done particularly well, benefiting from a higher incidence of flu in the US and cold, flu and sinus innovations," Mr Kapoor, pictured, added.
Nurofen and Durex also had "a strong performance," Mr Kapoor said. Reckitt said its condom brand's surging popularity was linked to major growth in China and the "roll-out" of its Real Feel condoms, designed to give "a natural skin-on-skin feeling". Elsewhere, Dettol sales are growing "very strongly" in emerging markets, the consumer goods group added.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments